Unlock instant, AI-driven research and patent intelligence for your innovation.

Tyrosine kinase inhibitors

a technology of tyrosine kinase and inhibitor, which is applied in the field of compounds and pharmaceutical compositions, can solve problems such as cell transformation leading to the development of cancer

Inactive Publication Date: 2021-03-18
RIGEL PHARMA
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text is simply saying that all the information in the citation is being introduced by reference. This means that the text is saying that the information in the citation is being incorporated by reference in its entirety, without any inconsistencies. The technical effect of this is that the information in the citation is being introduced in a way that ensures its accuracy and reliability.

Problems solved by technology

Deregulation of tyrosine kinases activity can result in cellular transformation leading to the development of cancer.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tyrosine kinase inhibitors
  • Tyrosine kinase inhibitors
  • Tyrosine kinase inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example 1

of 5-((6-Methoxy-7-(3-morpholinopropoxy)quinolin-4-yl)oxy)pyridin-2-amine (5′)

[0417]

Step 1-1: Synthesis of 4-(3-((4-Chloro-6-methoxyquinolin-7-yl)oxy)propyl)-morpholine (3′

[0418]A solution of 4-chloro-6-methoxyquinolin-7-ol (7.6 g, 36.3 mmol), 4-(3-chloro-propyl)morpholine (6.3 mL, 6.7 g, 40.9 mmol), potassium carbonate (15.0 g, 108.5 mmol) in DMF was allowed to stir at 90° C. for 22 h. LC / MS traces indicated the alkylation reaction is complete and hence, the mixture was cooled down to room temperature, diluted with water (240 mL) and extracted with EtOAc (5×75 mL). The combined organic layer was then washed with water (1×100 mL), brine (1×100 mL), dried (MgSO4), filtered and concentrated under reduced pressure to give a brown residue. Trituration with ethyl ether provided 10.2 g (83%) of 4-(3-((4-chloro-6-methoxyquinolin-7-yl)oxy)propyl)morpholine (3′) as a tan solid. 1H NMR (DMSO-d6, 300 MHz) δ 8.60 (d, J=4.9 Hz, 1H), 7.55 (d, J=4.8 Hz, 1H), 7.45 (s, 1H), 7.38 (s, 1H), 4.21 (t, J=...

example 2

of 8-Phenyl-3,4-dihydro-2H-1,4-ethano-1,5-naphthyridine-6-carboxylic Acid (13′)

[0421]

Synthesis of 1-(2-Amino-2-oxoethyl)pyridinium Chloride (6′)

[0422]A solution of 2-chloroacetamide (50.0 g, 524 mmol) and pyridine (41.5 g, 524 mmol) in 100 mL of acetonitrile was allowed to stir at 90° C. for 10 h. The suspension was cooled to room temperature, resulting solid filtered and washed with hexanes to provide 79.1 g (87%) of 1-(2-amino-2-oxoethyl)pyridinium chloride (6′) as a colorless solid.

Step 1: Synthesis of (Z)-2-Benzylidenequinuclidin-3-one (9′)

[0423]A solution of 3-quinuclidinone hydrochloride (7′, 50 g, 309 mmol), benzaldehyde (8′, 31.3 mL, 32.7 g, 167 5 mmol) and six pellets of sodium hydroxide in 150 mL of ethanol was allowed to reflux for 2 h. The reaction mixture was then allowed to cool down to room temperature and the resulting yellow precipitate was filtered, triturated with ethanol, filtered and dried to give 57.2 g (87%) of (Z)-2-benzylidenequinuclidin-3-one (9′) as a yell...

example 2a

of 4-Phenyl-7,8-dihydro-6H-5,8-ethanopyrido[3,2-d]pyrimidine-2-carboxylic Acid (13b′)

[0428]

Step 1: Synthesis of 4-Phenyl-4,6,7,8-tetrahydro-1H-5,8-ethanopyrido[3,2-d]pyrimidin-2(3H)-one (10a′)

[0429]To a solution of 2-benzylidenequinuclidin-3-one (9′, 57.2 g, 268 mmol) and urea (38.6 g, 643 mmol) in i-PrOH (500 mL), sodium t-butoxide (60.1 g, 535.6 mmol) was added and the resulting reaction mixture was allowed to stir at 100° C. for 3 h. After cooling to ambient temperature, the reaction mixture was poured into a flask containing water (1.5 L) and the resulting aqueous solution was extracted with 5% MeOH / DCM (3×100 mL), combined organic layers, dried (MgSO4), filtered and concentrated to provide a white solid upon trituration with ethyl ether. Residue from the mother liquor was chromatographed on silica gel eluting with DCM and 2% MeOH / DCM to provide another two batches of white solid upon trituration with i-PrOH. Combined three batches to obtain 34.9 g (51%) of 4-phenyl-4,6,7,8-tetr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
natural abundanceaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structureand pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, X, Y1, Y2, Y3 and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This is a divisional of application Ser. No. 16 / 424,619, filed May 29, 2019, which claims priority to U.S. Provisional Application Ser. No. 62 / 679,095 filed on Jun. 1, 2018, the disclosures of which are incorporated herein by reference in their entirety.BACKGROUNDField of Invention[0002]This invention relates to the field of compounds, pharmaceutical compositions, and methods of using the compounds and compositions containing them. This invention relates more particularly to the field of pyrimidoisoquinolone compounds and pharmaceutical compositions thereof, methods of inhibiting one or more kinases, such as one or more of the TAM (Tyro 3, Axl and Mer) receptor family with the compounds, and methods of treating and / or preventing disease with the compounds.TECHNICAL BACKGROUND[0003]In recent years, inhibition of specific cancer-associated tyrosine kinases has emerged as an important approach for cancer therapy. Tyrosine kinases as mediator...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D413/14C07D417/14C07D453/00C07D491/107
CPCC07D413/14C07D491/107C07D453/00C07D417/14C07D401/14C07D471/18C07D491/10A61P35/00
Inventor DARWISH, IHABYU, JIAXINKOLLURI, RAOHOLLAND, SACHA
Owner RIGEL PHARMA